CN102872074B - Application of Houttuynoid C in drugs for treating kidney cancer - Google Patents
Application of Houttuynoid C in drugs for treating kidney cancer Download PDFInfo
- Publication number
- CN102872074B CN102872074B CN201210417095.8A CN201210417095A CN102872074B CN 102872074 B CN102872074 B CN 102872074B CN 201210417095 A CN201210417095 A CN 201210417095A CN 102872074 B CN102872074 B CN 102872074B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- kidney cancer
- drugs
- application
- renal carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of Houttuynoid C in drugs for treating kidney cancer, belonging to the technical field of a new application of drugs. Through external MTT (Methyl Thiazolyl Tetrazolium) antineoplastic activity evaluation, the invention discovers that Houttuynoid C also has an obvious inhibition effect on the growth of human kidney cancer strains KC. Thus, Houttuynoid C can be applied to preparing anti-kidney cancer drugs and has good development and application prospects. The application of Houttuynoid C in drugs for treating kidney cancer disclosed by the invention is publicized for the first time; and as the skeleton type is brand new, Houttuynoid C has an unexpectedly strong inhibitory activity to kidney cancer cells.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid C, relate in particular to the application of Houttuynoid C in the anti-renal carcinoma medicine of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, have 74% to be natural product or derivatives thereof, if paclitaxel and derivant thereof are exactly the reasonable antitumor drug of effect clinically at present.Therefore, from natural product, find anticancer compound or lead compound has great importance.
The compound H outtuynoid C the present invention relates to is one and within 2012, delivers (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), purposes for the Houttuynoid C the present invention relates in preparation treatment renal carcinoma medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for kidney cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control for renal carcinoma simultaneously obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid C in preparing antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid C in the anti-renal carcinoma medicine of preparation, and the structural formula of Houttuynoid C is as shown in formula I:
The present invention finds by the evaluation of external MTT anti-tumor activity, and Houttuynoid C also has significant inhibitory action to the growth of human renal carcinoma cell strain KC, suppresses the IC of this 1 strain Growth of Cells
50value is respectively 1.56 ± 0.33 μ M μ M.Therefore, Houttuynoid C can, for the preparation of anti-renal carcinoma medicine, have good development prospect.
The purposes of the Houttuynoid C the present invention relates in preparation treatment renal carcinoma medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for kidney cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control for renal carcinoma simultaneously obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid C involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound H outtuynoid C tablet involved in the present invention:
Get 20 and digest compound Houttuynoid C, add 180 grams of conventional adjuvants preparing tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compound H outtuynoid C capsule involved in the present invention:
Get 20 and digest compound Houttuynoid C, add the conventional adjuvant of preparing capsule as 180 grams of starch, mix, encapsulatedly make 1000.
Below by pharmacodynamic experiment, further illustrate its pharmaceutically active.
Experimental example: adopt the growth inhibited effect of mtt assay assessing compound Houttuynoid C to human renal carcinoma cell strain
1. method: the cell in growth logarithmic (log) phase: human renal carcinoma cell strain KC(buys from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4concentration kind is in 96 orifice plates.After cell culture 24 h are adherent, suck original culture medium.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium containing 10% hyclone; It is 100 μ M that drug treating group is changed containing concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, 0.01 μ M, 0.001 μ M, the culture medium of the Houttuynoid C of 0.0001 μ M and 0.00001 μ M.Cultivate after 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator is cultivated 4 h, then along culture fluid top, suck 100 μ L supernatants, add 100 μ L DMSO, 10 min are placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
drug treating/ Δ OD
blank* 100.
2. result: Houttuynoid C has significant inhibitory action to the growth of human renal carcinoma cell strain KC.This compound suppresses the IC of human renal carcinoma cell strain KC growth
50value is respectively: 1.56 ± 0.33 μ M.
By above-described embodiment, shown, Houttuynoid C of the present invention has good inhibitory action to the growth of human renal carcinoma cell strain KC.Prove thus, it is active that Houttuynoid C of the present invention has anti-renal carcinoma, can be for the preparation of anti-renal carcinoma medicine.
Claims (1)
- The application of 1.Houttuynoid C in preparation treatment renal carcinoma medicine, described compound H outtuynoid C-structure as formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210417095.8A CN102872074B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in drugs for treating kidney cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210417095.8A CN102872074B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in drugs for treating kidney cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872074A CN102872074A (en) | 2013-01-16 |
| CN102872074B true CN102872074B (en) | 2014-04-16 |
Family
ID=47473745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210417095.8A Active CN102872074B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in drugs for treating kidney cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872074B (en) |
-
2012
- 2012-10-27 CN CN201210417095.8A patent/CN102872074B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| Houttuynoids A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata;Shao-Dan Chen, et al.;《ORGANIC LETTERS》;20120313;第14卷(第7期);1772-1775 * |
| Shao-DanChen et al..Houttuynoids A-E |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872074A (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861099B (en) | Application of Houttuynoid D in preparing medicine for treating endometrial cancer | |
| CN102861073B (en) | Application of Houttuynoid A in medicine for treating colorectal cancer | |
| CN102872074B (en) | Application of Houttuynoid C in drugs for treating kidney cancer | |
| CN102872072B (en) | Application of Houttuynoid B to preparing drugs for treating kidney cancer | |
| CN102872073B (en) | Application of Houttuynoid C in preparing drugs for treating ovarian cancer | |
| CN102861052B (en) | Application of Houttuynoid A in medicine for treating ileocecum cancer | |
| CN102861080B (en) | Application of Houttuynoid C in medicine for treating nasopharynx cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102872135B (en) | Application of Houttuynoid D in drug for treating renal cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102861074B (en) | Application of Houttuynoid B in medicine for treating bladder cancer | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102872080B (en) | Application of Houttuynoid A in drugs for treating cervical cancer | |
| CN102872138B (en) | Application of Houttuynoid C in drug for treating colorectal cancer | |
| CN102872085B (en) | Application of Houttuynoid A in medicines for treating breast cancer | |
| CN102872077B (en) | Application of Houttuynoid B in drugs for treating endometrial cancer | |
| CN102861078B (en) | Application of Houttuynoid D in medicine for treating prostatic cancer | |
| CN102861096B (en) | Application of Houttuynoid E in preparing medicine for treating cervical cancer | |
| CN102861077B (en) | Application of Houttuynoid D in medicine for treating cervical cancer | |
| CN102861062B (en) | Application of Houttuynoid C in endometrial cancer treatment medicine | |
| CN102861093B (en) | Application of Houttuynoid B in medicine for treating colorectal cancer | |
| CN102872075A (en) | Application of Houttuynoid E in drugs for treating breast cancer | |
| CN102861079B (en) | Application of Houttuynoid B in medicine for treating skin cancer | |
| CN102861070B (en) | Application of Houttuynoid E in medicine for treating tongue cancer | |
| CN102872139B (en) | Application of Houttuynoid C in drug for treating tongue cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: QIDONG TIANFEN ELECTRIC TOOL TECHNOLOGY INNOVATION Free format text: FORMER OWNER: WU JUNHUA Effective date: 20141126 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 226241 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141126 Address after: Qidong City, Jiangsu province 226241 Nantong lvsigang Tianfen electric tools trade city comprehensive building Patentee after: Qidong Tianfen Electric Tool Technology Innovation Center Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |